Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1970 2
1971 4
1972 4
1973 3
1974 2
1975 3
1978 1
1979 1
1982 3
1986 1
1987 1
1988 3
1989 3
1990 3
1991 2
1992 3
1994 2
1996 1
1997 1
1998 1
1999 1
2000 4
2001 3
2002 4
2003 3
2004 6
2006 2
2007 6
2008 3
2009 4
2010 3
2011 3
2012 4
2013 4
2014 1
2015 4
2016 6
2017 7
2018 6
2019 6
2020 6
2021 9
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

135 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. Among authors: lotem m. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Robert C, et al. Among authors: lotem m. Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345627 Clinical Trial.
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. Ascierto PA, et al. Among authors: lotem m. Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6. Nat Med. 2019. PMID: 31171878 Clinical Trial.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Schachter J, et al. Among authors: lotem m. Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16. Lancet. 2017. PMID: 28822576 Clinical Trial.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Robert C, et al. Among authors: lotem m. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639810 Free article. Clinical Trial.
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, Ascierto PA; KEYNOTE-022 international team. Ferrucci PF, et al. Among authors: lotem m. J Immunother Cancer. 2020 Dec;8(2):e001806. doi: 10.1136/jitc-2020-001806. J Immunother Cancer. 2020. PMID: 33361337 Free PMC article. Clinical Trial.
Adoptive cell therapy: past, present and future.
Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Cohen JE, et al. Among authors: lotem m. Immunotherapy. 2017 Jan;9(2):183-196. doi: 10.2217/imt-2016-0112. Immunotherapy. 2017. PMID: 28128715 Review.
Pathways and therapeutic targets in melanoma.
Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Shtivelman E, et al. Among authors: lotem m. Oncotarget. 2014 Apr 15;5(7):1701-52. doi: 10.18632/oncotarget.1892. Oncotarget. 2014. PMID: 24743024 Free PMC article. Review.
Familial lichen planus.
Katzenelson V, Lotem M, Sandbank M. Katzenelson V, et al. Among authors: lotem m. Dermatologica. 1990;180(3):166-8. doi: 10.1159/000248021. Dermatologica. 1990. PMID: 2187721 Review.
Ultraviolet radiation and cutaneous carcinogenesis.
Molho-Pessach V, Lotem M. Molho-Pessach V, et al. Among authors: lotem m. Curr Probl Dermatol. 2007;35:14-27. doi: 10.1159/000106407. Curr Probl Dermatol. 2007. PMID: 17641487 Review.
135 results